Genetron Holdings Limited, a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, has entered into an exclusive agreement with Jiangsu Fosun Pharmaceutical Sales, a subsidiary of Shanghai Fosun Pharmaceutical (Group), to commercialize Seq-MRD^®, a molecular diagnostic assay for the detection of minimal residual disease (MRD) in patients suffering from select hematologic cancers.

The partnership marks the launch of Genetron Health’s first product for hematologic cancer and MRD detection in the China market.

Under the agreement, Genetron Health and Jiangsu Fosun Pharma will work exclusively together to co-market and co-promote Seq-MRD^® in hematologic-focused hospitals and clinics across designated territories in China.

Both parties intend to serve patients afflicted by lymphoid malignancies, including acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphoid leukemia (CLL).

In order to promote Seq-MRD^®’s clinical applications, Jiangsu Fosun Pharma will bring a sizeable, experienced, hematologic cancer focused sales force and valuable relationships with clinics, hospitals and distributors to this collaboration. Genetron Health will provide technical and commercial support to the partnership; this will include promoting scientific studies, marketing, and conducting product-related training.